4D Pharma Shares Jump on Clinical Collaboration With Germany's Merck, Pfizer
By Adria Calatayud
Shares in 4D pharma PLC rose Monday after the company said it
has entered into a clinical-trial collaboration and supply
agreement with Germany's Merck KGaA and Pfizer Inc. for an oncology
Under the collaboration, the U.K. pharmaceutical company said it
will start a clinical trial this year to evaluate BAVENCIO, a
maintenance treatment for urothelial carcinoma co-developed by
Merck and Pfizer, in combination with 4D pharma's MRx0518, a
biotherapeutic product in development for the treatment of
The trial will evaluate the combination of BAVENCIO and MRx0518
as a first-line maintenance therapy for patients with locally
advanced or metastatic urothelial carcinoma that hasn't progressed
with first-line platinum-containing chemotherapy, 4D pharma
Urothelial carcinoma is a common type of bladder cancer.
Shares in 4D pharma at 0803 GMT were up 9.1% at 144 pence.
Write to Adria Calatayud at firstname.lastname@example.org
(END) Dow Jones Newswires
February 08, 2021 03:26 ET (08:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.